ATKOS: The ATtune Knee Outcome Study

Sponsor
Spaarne Gasthuis (Other)
Overall Status
Recruiting
CT.gov ID
NCT04247672
Collaborator
(none)
900
1
191.6
4.7

Study Details

Study Description

Brief Summary

To accomodate dissatisfied patients with a total knee arthroplasty (TKA) and improve outcomes, several knee systems have been developed. The cemented ATTUNE TKA shows superiority over other established knee systems at short-term, abating with longer follow-up. There have been no studies reporting on the results of the uncemented version of the ATTUNE. Therefore, the main objective of the current study was to report patient reported outcome measures (PROMs), survivorship and complications associated with the uncemented ATTUNE TKA.

Condition or Disease Intervention/Treatment Phase
  • Device: Total Knee Arthroplasty (uncemented rotating platform ATTUNE)

Detailed Description

Every year, 1.5 million total knee arthroplasties (TKA) are performed worldwide in patients whose joints have been severely affected by osteoarthritis, rheumatoid arthritis, or trauma, causing intense pain and loss of function. Due to the ageing society, these numbers are expected to have increased six-fold to 3.48 million cases annually by 2030. Even though joint replacement provides satisfactory and durable results for most patients, 20% is thought to still not be satisfied with their artificial joint. To accommodate this dissatisfied population and improve durability of implants even more, several knee systems have been developed over the years. One of the newest models is the ATTUNE knee system (DePuy, Warsaw, Indiana, USA). One of the landmark features is a gradually reducing radius in the geometry of the femoral component, more closely mimicking the anatomical patellofemoral joint and facilitating more natural femoral rollback during flexion. Comparisons of the cemented ATTUNE with previous knee systems show promising results in terms of patellofemoral outcomes, but fail to demonstrate definitive superiority in terms of all patient reported outcomes. Clinical superiority of the ATTUNE tends to abate with longer follow-up, implicating a possible superiority in the short-term recovery and return to activities. There is no follow-up study reporting the results of the uncemented ATTUNE. Moreover, all previously cited studies report better patellofemoral outcomes with patellar resurfacing, making it still unclear whether the implicated superior design changes of the femoral component hold ground without patellar resurfacing.

The primary objective is to report survivorship, complications and patient reported outcome measures associated with the uncemented ATTUNE rotating platform knee system. Secondary objectives are (1) evaluate patient reported (patellofemoral) outcomes (2) assess return to work and sport after TKA (3) translate and validate the Dutch version of the University of California, Los Angeles (UCLA) activity scale and (4) analyse psychologic factors (such as pain catastrophising and coping) and the impact on dissatisfaction following TKA.

Study Design

Study Type:
Observational
Anticipated Enrollment :
900 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The ATtune Knee Outcome Study: Prospective Evaluation of a Novel Uncemented Rotating Platform Total Knee Arthroplasty
Actual Study Start Date :
Feb 3, 2020
Anticipated Primary Completion Date :
Jan 22, 2024
Anticipated Study Completion Date :
Jan 22, 2036

Outcome Measures

Primary Outcome Measures

  1. Survivorship [10 year]

    Calculated by determining revision rate. Septic, aseptic and all-cause revision rates will be calculated seperately.

  2. Complication rate [10 year]

    All substantial complications associated with total knee arthroplasty will be registered and reported

  3. Forgotten Joint Score 12 (FJS-12) [10 year]

  4. Kujala Anterior Knee Pain Scale (AKPS) [10 year]

  5. Knee injury and Osteoarthritis Outcome Scale - Physical Function Short Form [10 year]

    KOOS-PS

  6. Numeric Rating Scale (NRS) [10 year]

    NRS on pain and satisfaction

  7. EuroQol 5 Dimensions, 3 Levels (EQ5D-3L) [10 year]

Secondary Outcome Measures

  1. 30 second chair stand test (30sCST) [1 year]

    The amount of times one can stand up and sit down from a chair in 30 seconds

  2. 40m Fast paced walk test (40m-FPWT) [1 year]

    The amount of seconds one does to walk 40 meters.

  3. Stair climb test (SCT) [1 year]

    The time one takes to walk a set of stairs up and down.

  4. Tegner activity rating scale [1 year]

    1-item questionnaire

  5. University of California, Los Angeles (UCLA) activity rating scale [1 year]

    1-item questionnaire

  6. Return to work [1 year]

    Assessed by a short self-composed questionnaire, which evaluates what kind of work the patients do, when they started after surgery and whether this is the same as their preoperative job

  7. Alignment [1 year]

    A long-leg radiograph is performed 1 year after surgery to assess mechanical alignment of the prosthesis with consideration of femur and tibia

  8. Patient Health Questionnaire (PHQ-2) [10 year]

    2-item questionnaire to screen for major depressive episodes

  9. Pain Self Efficacy Questionnaire (PSEQ) [10 year]

    Questionnaire to asses pain self efficacy

  10. Pain Catastrophizing Scale (PCS) [10 year]

    Explores pain catastrophizing and its relation to pain behaviour

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 90 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • End-stage osteoarthritis of the knee warranting joint replacement therapy.

  • Indicated for an ATTUNE total knee system as part of regular clinical practice.

  • Capability and willingness to sign informed consent and comply with follow-up procedures.

  • Capable enough in Dutch or English to be able to understand study procedures

Exclusion Criteria:
  • Unable or unwilling to sign informed consent and comply with follow-up

  • Indication for primary revision arthroplasty

  • Absolute indication for cemented fixation (decreased bone stock/quality of spongiosa)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Spaarne Gasthuis Hoofddorp Noord-Holland Netherlands 2134 TM

Sponsors and Collaborators

  • Spaarne Gasthuis

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Spaarne Gasthuis
ClinicalTrials.gov Identifier:
NCT04247672
Other Study ID Numbers:
  • 2019.0084
First Posted:
Jan 30, 2020
Last Update Posted:
Apr 27, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 27, 2022